Abstract Session 3

Co-Chair(s)

• 

  Andrzej Jakubowiak, MD, PhD

  Professor of Medicine
  The University of Chicago
• 

  Robert Orlowski, MD, PhD (he/him/his)

  Professor
  Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center
  Houston, Texas

Presentations:

• 16:30 - 16:40 East Coast USA Time

  (OA-17) MRI Response According to MY-RADS Correlates with MRD Negativity After Induction in Newly Diagnosed Multiple Myeloma: Results from the GMMG-HD7 Trial
  

  Abstract Presenter: Marina Hajiyianni, MD – Heidelberg Myeloma Center, Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
• 16:40 - 16:50 East Coast USA Time

  (OA-18) The Value of Progression-Free Survival (PFS) from the Perspectives of Patients with Multiple Myeloma (MM) and Treating Physicians: Quantitative Research Findings from Eight Countries
  

  Abstract Presenter: Aaron S. Rosenberg, MD, MS – UC Davis Comprehensive Cancer Center
• 16:50 - 17:00 East Coast USA Time

  (OA-19) Prospective Evaluation of Response Assessment in Newly-Diagnosed Multiple Myeloma with Combined use of 18F-FDG-PET/CT, Whole-Body Diffusion-Weighted MRI and MRD by Next-Generation Sequencing
  

  Abstract Presenter: Marco Talarico, marco.talarico – Università di Bologna - IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli"
• 17:00 - 17:10 East Coast USA Time

  (OA-21) Dynamic Frailty Analysis of Transplant-Ineligible (TIE) Patients with NDMM in the Phase 3 MAIA and CEPHEUS Trials of Daratumumab (Dara) + Lenalidomide-Dexamethasone (Rd) and Bortezomib-Rd (VRd)
  

  Abstract Presenter: Hira Mian, MD (she/her/hers) – McMaster University, Hamilton, ON, Canada
• 17:10 - 17:20 East Coast USA Time

  (OA-20) Temporal Trends in Infectious Risk Among Multiple Myeloma Patients Treated with Daratumumab: A Meta-Analysis
  

  Abstract Presenter: Alissa Visram, MD, MPH – Juravinski Cancer Centre / Hamilton Health Sciences